RSV infection complicating the therapy of pediatric malignancies: report of six cases.
We describe a series of six patients with symptomatic respiratory syncytial virus (RSV) infections while receiving anticancer chemotherapy. Particularly during epidemics in the general population, RSV remains a potential cause for morbidity and even mortality among children immunocompromised through the administration of anticancer chemotherapy and especially those being transplanted. We emphasize the importance of rapid diagnostics as well as prevention of the spread of the virus in a pediatric hematology/oncology unit.
Vettenranta
K
K
Children's Hospital, University of Helsinki, Finland.
Ukkonen
P
P
Saarinen
U M
UM
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000628:therapy; D018357:Respiratory Syncytial Virus Infections / Q000150:complications* / Q000188:drug therapy; D012254:Ribavirin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D012254:Ribavirin